Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli Lilly, the manufacturer of Mounjaro, eating smaller, more frequent meals, ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among adults. This powerful treatment features tirzepatide, which works with your ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

After four weeks, this increases to 0.5 milligrams. After another four weeks, it can go up to 1 milligram and then up to 2 milligrams four weeks after that. Mounjaro doses can be much higher.